Buy PARGY-LAD for sale online from USA vendor
Table of Contents
-
Introduction
- Overview of PARGY-LAD
- Historical Background
-
Chemistry
- Structural Features
- Core Polycyclic Structure
- Comparison with LSD
-
Dosage Guidelines
- Threshold, Light, Common, Strong, Heavy
-
Subjective Effects
- Physical Effects
- Cognitive Effects
- Auditory and Multi-sensory Effects
- Transpersonal Effects
-
Combinations
- Cannabis
- Dissociatives
- Alcohol
- Benzodiazepines
- Psychedelics
-
Toxicity and Harm Potential
- Lack of Scientific Studies
- Anecdotal Evidence
- Harm Reduction Practices
-
Tolerance and Addiction Potential
- Habit-Forming Speculation
- Tolerance Build-up
- Cross-tolerance with Psychedelics
-
Dangerous Interactions
- Lithium
- Cannabis
- Stimulants
- Tramadol
-
Legal Status
- Germany
- Latvia
- Switzerland
United Kingdom
Introduction
6-Propynyl-6-nor-Lysergic acid diethylamide, commonly known as PARGY-LAD, is an emerging synthetic psychedelic substance belonging to the lysergamide chemical class. While sharing structural similarities with LSD, it is recognized for its relative obscurity and lack of distinctive features.
Historical Background
First acknowledged as an LSD analog by Alexander Shulgin in his influential book TiHKAL ("Tryptamines I Have Known and Loved"), PARGY-LAD has gained attention for its reduced potency compared to LSD, with reported activity starting at 160 μg and reaching full potential at 500 micrograms.
Pharmacology and Usage
Despite its growing presence in the market alongside research chemical lysergamides like AL-LAD and ETH-LAD, PARGY-LAD remains poorly studied. Limited information exists regarding its pharmacological properties, metabolism, and toxicity. This scarcity of data, coupled with its minimal history of human use, underscores the need for caution when considering its consumption.
Chemistry
PARGY-LAD, a synthetic alkaloid of the lysergamide family, shares a core polycyclic structure with LSD but differs in the substitution at R6 with a propynyl group instead of a methyl group. Its structure encompasses a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid).
Dosage Guidelines
Understanding the dosage of PARGY-LAD is crucial for safe consumption. The recommended dosage ranges include:
- Threshold: 50 µg
- Light: 125 - 275 µg
- Common: 275 - 500 µg
- Strong: 500 - 700 µg
- Heavy: 700 µg and above.
Subjective Effects
Disclaimer: The following effects are based on anecdotal reports and the Subjective Effect Index (SEI). Caution is advised, as effects may vary, and higher doses can lead to unpredictable outcomes, including adverse effects such as addiction, severe injury, or death.
Physical Effects
- Spontaneous physical sensations
- Physical euphoria
- Stimulation
- Bodily control enhancement
- Stamina enhancement
- Headaches
- Nausea
- Appetite suppression
- Dehydration
- Difficulty urinating or Frequent urination
- Temperature regulation suppression
- Increased bodily temperature
- Increased blood pressure
- Increased heart rate
- Increased perspiration
- Muscle contractions
- Muscle cramps
- Muscle spasms
- Olfactory hallucination
- Mouth numbing
- Excessive yawning
- Watery eyes
- Pupil dilation
- Vasoconstriction (citation needed)
- Wakefulness
- Teeth grinding
- Seizure (potential risk, but no documented cases with PARGY-LAD).
Cognitive Effects
- Analysis enhancement
- Anxiety & Paranoia
- Personal bias suppression
- Novelty enhancement
- Conceptual thinking
- Introspection
- Immersion enhancement
- Increased music appreciation
- Increased sense of humor
- Laughter fits
- Thought acceleration
- Thought connectivity
- Thought loops
- Language suppression
- Memory suppression
- Confusion
- Déjà vu
- Time distortion (pronounced relative to other psychedelics)
- Wakefulness
Auditory Effects
- Auditory enhancement
- Auditory distortion
Multi-sensory Effects
Synaesthesia (rare and non-reproducible)
Transpersonal Effects
These effects, considered rare and less reproducible, depend heavily on contextual factors such as the user's set and setting.
- Existential self-realization
- Spirituality enhancement
- Feelings of eternalism
- Perception of self-design
- Feelings of interdependent opposites
Unity and interconnectedness
PARGY-LAD: Exploring Combinations, Toxicity, and Legal Status
Combinations
Cannabis
Combining PARGY-LAD with cannabis can intensify and prolong both visual and cognitive effects, but caution is advised for inexperienced users. Some report heightened visuals with THC concentrates like hashish compared to cannabis flower, yet this combination may increase anxiety, confusion, and psychosis aspects. Prudence is essential when experimenting with this blend.
Dissociatives
When paired with dissociatives, PARGY-LAD enhances geometry, euphoria, dissociation, and hallucinatory effects. The combination may result in more vivid visuals, internal hallucinations, and confusion compared to dissociatives alone.
Alcohol
While not typically recommended due to potential dehydration and nausea, low doses of alcohol with PARGY-LAD can take the edge off a trip, akin to benzodiazepines. However, moderate to high doses may negatively impact the psychedelic experience, causing physical fatigue and stress on the body.
Benzodiazepines
Combining benzodiazepines with PARGY-LAD can reduce cognitive, physical, and visual effects, providing an efficient way to mitigate a challenging trip. Caution is urged due to the high addiction potential of benzodiazepines.
Psychedelics
Combining PARGY-LAD with other psychedelics intensifies their effects synergistically. However, due to the unpredictable nature of this synergy, starting with lower dosages than those taken individually is recommended.
Toxicity and Harm Potential
The toxicity and long-term health effects of PARGY-LAD remain unexplored in scientific contexts. Anecdotal evidence suggests no significant negative health effects at low to moderate doses when used sparingly. However, caution and harm reduction practices are strongly advised, especially considering the lack of comprehensive research on the substance.
Tolerance and Addiction Potential
While formal studies are lacking, PARGY-LAD is speculated to be non-habit-forming, with a potential decrease in the desire to use it with repeated administration. Immediate tolerance builds after ingestion, taking 5-7 days for a 50% reduction and 14 days to return to baseline. Cross-tolerance with other psychedelics is observed, diminishing their effects.
Dangerous Interactions
Several substances can interact dangerously with PARGY-LAD. Notable interactions include:
- Lithium: Increases the risk of psychosis and seizures.
- Cannabis: Heightens the risk of adverse psychological reactions like anxiety and psychosis.
- Stimulants: Elevates the risk of anxiety, paranoia, panic attacks, and thought loops.
- Tramadol: Lowers the seizure threshold, potentially triggering seizures.
- Always conduct independent research to ensure the safety of combining substances.
Legal Status
- Germany: Controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019.
- Latvia: Illegal due to an LSD structural analog classification.
- Switzerland: Not specifically controlled under certain regulations, making it potentially legal.
United Kingdom: Classified as a Class A drug under the Misuse of Drugs Act since January 7, 2015.
FAQ (Frequently Asked Questions)
Q1: What is PARGY-LAD?
PARGY-LAD, or 6-Propynyl-6-nor-Lysergic acid diethylamide, is a synthetic psychedelic substance belonging to the lysergamide chemical class. It is known for its structural similarities to LSD.
Q2: How does PARGY-LAD differ from LSD?
While sharing a core polycyclic structure with LSD, PARGY-LAD substitutes a propynyl group at R6 instead of a methyl group, making it distinct.
Q3: What are the recommended dosage guidelines for PARGY-LAD?
Dosages include threshold (50 µg), light (125 - 275 µg), common (275 - 500 µg), strong (500 - 700 µg), and heavy (700 µg and above).
Q4: Are there potential combinations with PARGY-LAD?
Yes, combinations with substances like cannabis, dissociatives, alcohol, benzodiazepines, and other psychedelics can influence and enhance its effects. Caution is advised, and details are provided in the article.
Q5: What is known about the toxicity and harm potential of PARGY-LAD?
Scientific studies are lacking, and anecdotal evidence suggests no significant health effects at low to moderate doses. Caution and harm reduction practices are strongly recommended.
Q6: Is PARGY-LAD habit-forming?
While formal studies are unavailable, it is speculated that PARGY-LAD is not habit-forming, and repeated administration may decrease the desire to use it.
Q7: What are the dangerous interactions with PARGY-LAD?
Interactions with substances like lithium, cannabis, stimulants, and tramadol can pose risks. Independent research is crucial for ensuring safety.
Q8: What is the legal status of PARGY-LAD in different countries?
Legal status varies, with specifics outlined for Germany, Latvia, Switzerland, and the United Kingdom. Always check local regulations for the most up-to-date information.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics